Literature DB >> 8581517

Leflunomide interferes with pyrimidine nucleotide biosynthesis.

H M Cherwinski1, N Byars, S J Ballaron, G M Nakano, J M Young, J T Ransom.   

Abstract

Leflunomide is an anti-inflammatory and immunosuppressive agent which blocks proliferation of transformed cells and mitogen stimulated normal lymphocytes but does not block T cell signaling mechanisms at antiproliferative concentrations. These properties are consistent with a mechanism involving interference with nucleotide metabolism. Leflunomide had anti-proliferative activity against all cells tested here. The anti-proliferative activities could be reversed by addition of uridine or cytidine to the cultures although some species and cellular differences were observed. Purine nucleotides had no effect. Measurements of nucleotide pools in a human T cell line and mitogen stimulated rat spleen cells treated with leflunomide showed that leflunomide preferentially reduces pyrimidine nucleotide levels. These results indicate that inhibition of pyrimidine biosynthesis is responsible for the anti-proliferative effects of leflunomide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8581517     DOI: 10.1007/bf01796261

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  21 in total

1.  Malononitrilamides (MNA 279 and MNA 715) have therapeutic activity in acute and chronic relapsing experimental allergic encephalomyelitis (EAE).

Authors:  H U Schorlemmer; R R Bartlett
Journal:  Inflamm Res       Date:  1997-08       Impact factor: 4.575

2.  Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression.

Authors:  A S Chong; H Gebel; A Finnegan; E E Petraitis; X L Jiang; H N Sankary; P Foster; J W Williams
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

Review 3.  Mechanisms of action of mycophenolic acid.

Authors:  A C Allison; W J Kowalski; C D Muller; E M Eugui
Journal:  Ann N Y Acad Sci       Date:  1993-11-30       Impact factor: 5.691

4.  Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.

Authors:  S F Chen; L M Papp; R J Ardecky; G V Rao; D P Hesson; M Forbes; D L Dexter
Journal:  Biochem Pharmacol       Date:  1990-08-15       Impact factor: 5.858

5.  Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase.

Authors:  D J Price; J R Grove; V Calvo; J Avruch; B E Bierer
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

6.  Promotion of corneal allograft survival with leflunomide.

Authors:  J Y Niederkorn; L S Lang; J Ross; J Mellon; S M Robertson
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-09       Impact factor: 4.799

7.  Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation.

Authors:  A S Chong; A Finnegan; X Jiang; H Gebel; H N Sankary; P Foster; J W Williams
Journal:  Transplantation       Date:  1993-06       Impact factor: 4.939

8.  Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.

Authors:  T Mattar; K Kochhar; R Bartlett; E G Bremer; A Finnegan
Journal:  FEBS Lett       Date:  1993-11-15       Impact factor: 4.124

9.  The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism.

Authors:  H M Cherwinski; D McCarley; R Schatzman; B Devens; J T Ransom
Journal:  J Pharmacol Exp Ther       Date:  1995-01       Impact factor: 4.030

10.  Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing.

Authors:  R Shimonkevitz; J Kappler; P Marrack; H Grey
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Leflunomide: a review of its use in active rheumatoid arthritis.

Authors:  A Prakash; B Jarvis
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A.

Authors:  K Thoss; S Henzgen; P K Petrow; D Katenkamp; R Brauer
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

3.  Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.

Authors:  Pei Chen; Huiyu Feng; Juan Deng; Yufei Luo; Li Qiu; Changyi Ou; Weibin Liu
Journal:  J Neurol       Date:  2015-10-29       Impact factor: 4.849

4.  Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.

Authors:  A G Vlassenko; B Thiessen; B J Beattie; M G Malkin; R G Blasberg
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 5.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 6.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

7.  The effect of mitochondrial dysfunction on cytosolic nucleotide metabolism.

Authors:  Claus Desler; Anne Lykke; Lene Juel Rasmussen
Journal:  J Nucleic Acids       Date:  2010-08-24

Review 8.  Teriflunomide: a review of its use in relapsing multiple sclerosis.

Authors:  Karly P Garnock-Jones
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

9.  Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients.

Authors:  Nicolae Leca; Kimberly A Muczynski; Jonathan A Jefferson; Ian H de Boer; Jolanta Kowalewska; Elizabeth A Kendrick; Raimund Pichler; Connie L Davis
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-27       Impact factor: 8.237

10.  Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; P Ghiorzo; C Pizzorni; C Craviotto; B Villaggio
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.